Skip to main content

Provention Bio shares more than triple on diabetes prevention study results

Shares of Provention Bio, a New Jersey-based drug company that went public last year, more than tripled Monday after the company's experimental medicine appeared to delay onset of type 1 diabetes in a clinical trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.